E-2 Visa Business Plan for a Pharmacy: Investment, Staffing, and Regulatory Requirements

Pharmacies — whether independent community pharmacies, compounding pharmacies, or specialty pharmacies focused on particular patient populations — involve capital outlays that comfortably support the substantial-investment analysis. A de novo independent pharmacy commonly requires $300,000 to $600,000 to open: leasehold improvements, automated dispensing equipment, pharmacy management software, initial inventory, licensing fees, and working capital. Acquiring an established pharmacy is typically more expensive but brings prescription volume history that strengthens financial projections.

The principal risk in a pharmacy E-2 application is the develop-and-direct requirement under 8 CFR 214.2(e)(2). Because many states require a licensed pharmacist to serve as pharmacist-in-charge (PIC) of a retail pharmacy, investors who are not themselves licensed pharmacists sometimes structure the business so the pharmacist runs clinical operations while the investor handles only administrative tasks. If the business plan does not clearly show the investor exercising genuine executive authority — over strategy, finance, marketing, and vendor relationships — rather than deferring entirely to the PIC, the develop-and-direct element is vulnerable.

The investment section must enumerate every pre-operational expenditure and demonstrate that the funds are irrevocably committed under 9 FAM 402.9-6(B). For a de novo pharmacy, the itemized list typically includes: commercial lease deposit and leasehold improvements (dispensary build-out, HVAC, security); pharmacy management software and hardware; initial drug inventory; point-of-sale and insurance billing systems; DEA registration fee (Form 224) and state pharmacy license application fees; professional liability and general commercial insurance; signage; and working capital through the first 90 to 120 days.

For the acquisition of an existing pharmacy, the investment section must address the purchase price and how it relates to the appraised value. Under 9 FAM 402.9-7(B), the proportionality test applies: the investment must represent a substantial proportion of the total cost of the enterprise. For a $500,000 pharmacy acquisition, an investor contributing $400,000 of their own funds satisfies the test, but the full $500,000 acquisition price is the relevant denominator — not just the cash portion. The business plan should include the pharmacy's historical financials, a business valuation or broker's opinion of value, and the purchase agreement.

• Leasehold improvements: signed commercial lease and contractor quotes or invoices
• Equipment: pharmacy management system, dispensing hardware, will-call units, cold storage — itemized with purchase agreements
• Initial inventory: projected opening inventory list with estimated cost by therapeutic category
• DEA registration (Form 224) and state board of pharmacy license: copies of applications and fee receipts
• Pharmacy billing software and insurance credentialing setup: vendor agreements
• Working capital: bank statement showing funds held in the business account after all pre-opening expenditures

Every state requires a licensed pharmacist-in-charge for the physical dispensing operations of a retail pharmacy. If the E-2 investor does not hold a U.S. pharmacy license, they must hire a PIC. This is permissible; the investor does not need to personally perform every operational function. Under 8 CFR 214.2(e)(2) and 9 FAM 402.9-4(D), the requirement is that the investor directs the enterprise — meaning they make the significant executive and business decisions — not that they personally dispense medications.

The business plan's management section must precisely define this division. The PIC is responsible for clinical operations: verifying prescriptions, counseling patients, managing pharmacy technician performance, and ensuring regulatory compliance at the dispensary level. The investor is responsible for the business: lease and vendor negotiations, financial management, marketing to prescribers and patients, payroll, strategic partnerships, and capital allocation. Both roles must be described concretely, and the investor's role must look like genuine executive leadership rather than a passive ownership interest. Officers look at whether removing the investor from the enterprise would materially affect its direction — if the PIC could run the pharmacy identically without the investor, the develop-and-direct element is not satisfied.

The staffing section must identify every position the business will hire, the expected hiring timeline, and cost. A typical independent pharmacy structure includes the pharmacist-in-charge, one or two pharmacy technicians, and a front-end cashier or clerk. Larger operations, compounding pharmacies, or specialty pharmacies may require additional clinical or technical staff.

Each position should appear in the financial model with a salary or hourly wage drawn from local market data — the U.S. Bureau of Labor Statistics Occupational Employment and Wage Statistics program publishes pharmacist and technician wages by metropolitan area. The staffing plan should also note any licensing requirements for the positions: pharmacy technicians are licensed or registered in most states, and some require national certification through the PTCB program. These requirements have cost and timeline implications that a credible plan will acknowledge.

From a marginality perspective under 9 FAM 402.9-9(A), a pharmacy that begins with one PIC and one technician but projects growth to a full team within 24 months, tied to growing prescription volume, presents a defensible non-marginality argument. The projections should connect staffing growth explicitly to patient volume — prescriptions dispensed per day is the standard unit — so the officer can trace the connection between revenue assumptions and headcount growth.

DEA registration under 21 CFR Part 1301 is required before a pharmacy can receive, stock, or dispense controlled substances. DEA Form 224 (retail pharmacy registration) must be filed and approved before opening; approval typically takes four to six weeks. The business plan should include the DEA application or confirmation of submission if already filed, or explain the expected timing if pending E-2 approval.

State board of pharmacy licensure is a separate process. Each state requires a premises inspection before a dispensing license is issued, meaning the physical location must be built out before licensure can be completed. The business plan should describe where in the licensure process the investor stands and the estimated timeline to opening.

If the pharmacy intends to participate in Medicare Part D or Medicaid — which most independent pharmacies must in order to serve the broadest patient base — CMS credentialing typically requires 60 to 90 days. The business plan's financial projections must account for this enrollment timeline, since Medicare and Medicaid revenue cannot begin until credentialing is complete.

The financial model for a pharmacy E-2 application rests on prescription volume as the primary revenue driver. The projection should state the expected average prescriptions dispensed per day in year one and how that volume grows through year five, with growth tied to stated assumptions — marketing to local prescribers, patient loyalty as the pharmacy establishes itself, or specialty drug contracts with physician groups or long-term care facilities.

Pharmacy economics differ from most retail businesses. Revenue is largely driven by reimbursement rates negotiated with pharmacy benefit managers and state Medicaid programs, not by retail price-setting. Typical independent pharmacy financial benchmarks: gross margin on pharmaceuticals of 20 to 25 percent, front-end retail margin of 35 to 45 percent on OTC items, total operating expenses consuming 15 to 20 percent of revenue in a mature operation. Year one is commonly below those benchmarks as patient volume builds. Five-year projections should show the trajectory from break-even through stabilization, with a break-even point expressly calculated and included.

The marginality analysis requires that the projections demonstrate the enterprise will generate income beyond the investor's own compensation within a reasonable horizon. For a pharmacy with $400,000 or more invested, 9 FAM 402.9-9(A) generally allows a two-to-three-year ramp period before the enterprise is expected to reach full non-marginal scale.

• Revenue drivers: prescriptions per day times average reimbursement, broken down by payer mix (commercial, Medicare Part D, Medicaid, cash pay)
• Cost of goods: pharmaceutical inventory cost as a percentage of prescription revenue, tracked separately from front-end COGS
• Payroll: pharmacist(s), technicians, front-end staff — use BLS OES wage data for the specific metro area
• Occupancy: rent, utilities, professional liability insurance, and controlled-substance coverage
• Break-even: state the daily prescription volume required to cover all fixed and variable costs
• Owner compensation: state explicitly as a line item, distinguishable from residual net income

When the E-2 investment involves purchasing an existing pharmacy, the business plan must incorporate the acquisition context. Officers look for evidence that the purchase price represents fair market value, that the investor conducted appropriate due diligence, and that the investor — not a seller staying on in a de facto management role — will control the enterprise.

The business plan appendix for an acquisition should include: a letter of intent or executed asset purchase agreement, the seller's tax returns for the most recent three years, a prescription volume summary for the most recent 12 months, any PBM contracts transferring to the buyer, and a pharmacist transition plan if the existing PIC is leaving. A broker's opinion of value or independent business valuation significantly strengthens the investment's credibility under the proportionality test. The investor's narrative should describe what new management direction will occur — new payer contracts, specialty services, or patient outreach strategies that differ from the prior owner's approach — to demonstrate active development and direction of the enterprise.

The most frequent error is framing the investor's role as the pharmacist-in-charge without confirming that the investor holds a U.S. pharmacy license. A pharmacist licensed only in a foreign country cannot serve as PIC in any U.S. state without completing licensure by examination or endorsement, which takes months and is not guaranteed. A plan that depends on the investor serving as PIC without confirming U.S. license status will create an inadmissibility or credibility problem.

A second common mistake is omitting the DEA and state board registration timeline from the financial projections. If the pharmacy cannot open until those approvals are issued, the revenue timeline must reflect that delay. A plan showing revenue from month one when the regulatory approvals needed to legally dispense prescriptions are still pending undermines the plan's credibility with any adjudicator familiar with the pharmacy licensing process.

A third problem is projecting prescription volume without explaining why patients will choose an independent pharmacy over a chain. The market analysis section should document the unmet need — a geographic gap in independent pharmacy access, a patient population with specialized medication needs such as compounding, or a prescriber base that values personal pharmacist relationships — that underpins the revenue model.